Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AtorvaStatin Postpartum and Reduction of Cardiovascular risK (SPARK): A Randomized Placebo-controlled Trial of Atorvastatin Postpartum for Reduction of Cardiovascular Risk

NCT06632379 is registered in ClinicalTrials.gov with Ohio State University as lead sponsor.

NCT NCT06632379
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06632379 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AtorvaStatin Postpartum and Reduction of Cardiovascular risK (SPARK): A Randomized Placebo-controlled Trial of Atorvastatin Postpartum for Reduction of Cardiovascular Risk
Lead sponsor
Ohio State University
Phase
Phase 4
Overall status
Recruiting
Start date
October 3, 2025
Completion date
December 15, 2026
Enrollment
76 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gestational hypertension, hypertensive disorders of pregnancy, preeclampsia